The transferable exclusivity voucher idea being proposed by the European Commission as a way of stimulating the development of new antibiotics in the EU is a “narrow and inefficient” mechanism that could actually exacerbate the problems related to antimicrobial resistance (AMR), says the European Public Health Alliance.
Under the scheme, a company that brought a new antimicrobial to the market would receive a “transferable exclusivity extension” (TEE)...





